Spiriva vs. Pulmicort

See how Spiriva and Pulmicort compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Spiriva is a long-acting anticholinergic bronchodilator approved for COPD and asthma, while Pulmicort is an inhaled corticosteroid approved only for asthma.

  • Spiriva is taken once daily, but Pulmicort requires twice-daily dosing to control airway inflammation.

  • Neither drug relieves sudden asthma or COPD flare-ups; both are for long-term maintenance only.

Spiriva vs. Pulmicort Drug Summary

Spiriva

Spiriva is a long-acting muscarinic antagonist (LAMA) that relaxes airway muscles to ease breathing in COPD and, with the Respimat device, asthma. It is inhaled once daily using either the HandiHaler or Respimat device, depending on the condition being treated. Spiriva has been used clinically for over two decades.

Pulmicort

Pulmicort is an inhaled corticosteroid that reduces airway inflammation to prevent asthma symptoms over time. It is inhaled twice daily through the Flexhaler dry powder device, and a nebulized Respules version is available for younger children. Pulmicort is approved only for asthma, not COPD.

Spiriva vs. Pulmicort Side Effects

Spiriva

Most common
pharyngitis (up to 12.5%)
sinusitis (up to 6.5%)
headache (up to 5.7%)
dry mouth (up to 5.1%)

Pulmicort

Most common
nasopharyngitis (up to 9.3%)
pharyngitis (up to 2.7%)
nasal congestion (up to 2.7%)
rhinitis allergic (up to 2.2%)

Spiriva vs. Pulmicort Dosage

Spiriva

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mcg once daily At the start
Maximum dose 18 mcg once daily If needed
Dose changes 2 increases As tolerated

Pulmicort

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 180 mcg twice daily At the start
Maximum dose 720 mcg twice daily If needed
Dose changes 2 increases As tolerated

Spiriva vs. Pulmicort Indications

Spiriva

Spiriva is FDA-approved for long-term maintenance of COPD, including chronic bronchitis and emphysema, and for reducing COPD exacerbations. The Respimat device also carries an asthma maintenance indication for patients 6 and older. It is not intended for relief of sudden bronchospasm.

  • Long-term COPD maintenance therapy

  • Reduces COPD exacerbations

  • Asthma maintenance (Respimat, ages 6+)

  • Not a rescue inhaler for acute symptoms

Pulmicort

Pulmicort is FDA-approved for long-term maintenance of asthma in patients 6 and older, working as a preventive anti-inflammatory therapy. It is sometimes used off-label to manage eosinophilic esophagitis. Pulmicort is not approved for COPD or for treating acute asthma attacks.

  • Long-term asthma maintenance therapy

  • Off-label use for eosinophilic esophagitis

  • Not approved for COPD

  • Not a rescue inhaler for acute asthma

Spiriva vs. Pulmicort Pros and Cons

Spiriva

Spiriva offers once-daily dosing and is approved for both COPD and asthma, giving it broader use than Pulmicort. Its anticholinergic mechanism differs from inhaled steroids, so it carries a distinct side effect profile, including dry mouth and urinary retention risk. It typically costs more out of pocket than Pulmicort.

Pros

  • Once-daily dosing versus twice-daily for Pulmicort

  • Approved for both COPD and asthma (Respimat)

  • Over two decades of established clinical use

  • Available in two inhaler devices for different needs

Cons

  • Costs roughly $600 to $630 per month without insurance, before savings programs

  • Not approved for treating acute bronchospasm

  • HandiHaler device limited to adult COPD patients

  • May worsen glaucoma or urinary retention symptoms

Pulmicort

Pulmicort works directly on airway inflammation, making it a mainstay for long-term asthma control rather than bronchodilation. It requires twice-daily use but has a milder systemic side effect profile than many other therapies. It generally costs less out of pocket than Spiriva.

Pros

  • Costs roughly $200 to $350 per month without insurance, before savings programs

  • Targets airway inflammation directly, not just muscle relaxation

  • Available as Respules for children under 6

  • Lower risk of anticholinergic side effects like dry mouth

Cons

  • Requires twice-daily dosing instead of once daily

  • Risk of oral thrush with inhaled corticosteroid use

  • Contains trace milk proteins, risky for severe milk allergy

  • Not approved for COPD treatment

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.